Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06617208

Prognostic IntraOperative Biomarkers ideNtification in Tumor rElatEd suRgery

INTRODUCTION AND RATIONALE

Aggressive brain tumors like glioma have the ability to infiltrate the surrounding healthy brain tissue, disrupting normal neuronal activities and leading to impaired motor and cognitive functions, as well as causing epilepsy. This malignant brain tumor is considered one of the most challenging cancers to treat, with a median survival of 12 to 15 months. Recent findings on direct neuron-tumor interactions indicate that abnormal brain activity in the regions surrounding brain tumors may contribute to develop epilepsy and accelerating tumor growth. Tumors tend to 'fuel' themselves with neurotransmitters released during its 'daily' neuronal firing. Hyperactive neurons in the peritumoral cortex can form excitatory electrochemical synapses with surrounding tumor cells, creating direct communication pathways within the peritumoral microenvironment, which aids in the progression and proliferation of tumor cells via direct and paracrine signalling pathways. However, the specific features of this abnormal brain activity in the peritumoral cortex have not been fully clarified and information on the pathological changes of neuronal activity in glioma patients is largely lacking. To advance more effective treatment strategies, it is crucial to better understand the complex interactions between the tumor and the brain.

This is especially important for the group of patients of which many perceive diminished quality of life because of epilepsy, cognitive functioning and language problems after tumor surgery. Furthermore, a thorough understanding is lacking of what tumor resection does to the original hyperactive peritumoral cortex and if resecting this is beneficial for improving postoperative outcome both for epilepsy as well as regarding survival. Therefore, identifying the hyperactive peritumoral cortex and directly addressing its impacts on the brain function and long-term surgical outcome could be a promising novel therapeutic strategy for treating glioma patients.

STUDY AIM

The measurement focuses on capturing neuronal activity at single-neuron resolution in the peritumoral cortex of glioma patients using cortical depth electrodes. It is well-established that gliomas can remodel the surrounding brain tissue, leading to abnormal neuronal hyperactivity, which contributes to tumor progression and epilepsy. However, the specific neuronal patterns and underlying mechanisms of these changes are not yet fully understood. This study will aim to collect detailed single-neuron recordings in this context, enabling us to map the precise neurophysiological disruptions caused by gliomas. On the long term, this research could lay the groundwork in identifying novel therapeutic approaches by providing critical in-sights into how gliomas alter brain function.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age between 18 yrs and 90 yrs old with radiologically diagnosed GBM
  • Eligible for surgery according to standard practices. If suitable and necessary according to standard practices, awake surgery is also permitted.
  • Written Informed consent.

Exclusion criteria

  • Inability to give consent because of or language barrier
  • Psychiatric history
  • Previous brain tumour surgery or radiotherapy
  • Severe aphasia or dysphasia
  • Patient has pacemaker or other implanted electrical device such as vagal nerve stimulator or other

Treatment and study plan

Neuropixel probe recording

Device

Neuropixel recordings captures neuronal activity at the single-neuron level across the layers of the cortex.

Other names: laminar electrophysiology, cortical depth electrophysiology

Primary outcomes

  1. Number of Successful Neuropixels Probe Recordings During Glioma Surgeries

    Time frame: From the beginning to end of tumor surgery

    Description:

    The primary outcome measure is the number of successful Neuropixels depth electrode recordings achieved during glioma surgeries. Success is defined as:

    Sterility: No postoperative infections, assessed by clinical follow-up and microbiological testing.

    Signal Quality: Signal-to-noise ratio (SNR) above 30 dB, as measured during and after surgery through electrophysiological software.

    Device Integrity: No fractures or damage to the Neuropixels probe, verified by post-procedure inspection.

    Training Efficiency: Setup time and error reduction during the recording process, recorded across surgeries to assess team proficiency.

Secondary outcomes

  1. Prognostic Biomarker Identification (Unit: Number of Isolated Single Neurons with Tumor-Modulated Activity):

    Time frame: From the beginning to end of surgery

    The secondary outcome will focus on identifying prognostic biomarkers through intra-operative recordings using Neuropixels. This includes measuring the number of single neurons isolated with distinct spiking or waveform characteristics that correlate with tumor pathology. The outcome will be quantified as the number of neurons showing unique tumor-related activity patterns (e.g., altered firing rates, waveform morphology) across patients undergoing surgery.

Study contacts

Contact information is provided by the study sponsor or research team.

Arnaud Vincent, MD PhD

CONTACT

[email protected]

Koen van der Kuil

CONTACT

[email protected]

+31641078801

Sponsors and collaborators

Lead sponsor

Erasmus Medical Center

Other

Registry information

Official study title

Prognostic IntraOperative Biomarkers ideNtification in Tumor rElatEd suRgery (PIONEER Study)

Acronym: PIONEER

Important dates

Study start
2025
Primary completion
2029
Study completion
2029
First posted
Sep 27, 2024
Registry last updated
Aug 8, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.